Phillips-Medisize Expands Global Manufacturing Capacity, Capabilities and Collaborations to Drive Innovations in Drug Delivery, Diagnostics and Medical Technology

The leader in medical and pharmaceutical solutions is set to expand manufacturing from new and expanded production facilities and R&D centers in Poland, China and U.S

End-to-end capabilities optimize the design, development and manufacture of world-class healthcare products and solutions while reducing time, cost and risk

State-of-the-art collaborations with Eyevensys, GlucoModicum and Credence MedSystems accelerate delivery of technological breakthroughs and next-generation products

HUDSON, Wisconsin., 20 October 2021 / PRNewswire / – Phillips-Medisize, a Molex Company and a Leader in the Design and Manufacture of Drug Delivery, Diagnostic and MedTech Devices, Announces Expansion of Its Global Manufacturing Footprint, Along with Expanded Design, Development and Manufacturing Capabilities of products to streamline the delivery of breakthrough products and solutions. The company’s global reach now includes 36 world-class facilities with end-to-end scalable capabilities designed to help customers bring breakthrough products to market quickly and efficiently from anywhere in the world.

Growing footprint of Phillips-Medisize’s 36 world-class facilities around the world.

“As a preferred partner to major global customers, we continually invest in new talent and technologies that increase Phillips-Medisize’s capacity and capabilities across the value chain,” said Paul Chaffin, President, Medical and Pharmaceutical Solutions, Molex. “Our global reach and expanded resources will allow us to solve complex development and manufacturing challenges while meeting growing customer demands for more localized production, supply chain management and go-to-market strategies. accelerated. “

Growing footprint for local support, globally

To meet the growing production demands of mainland customers Europe, Phillips-Medisize is building a state-of-the-art medical manufacturing facility in Katowice, Poland. Scheduled to open in 2022, the site will complement the production sites and innovation centers of Asia, Europe, India, Mexico and North America. Phillips-Medisize is also expanding its production capacity to Suzhou, China to serve global and regional pharmaceutical and MedTech customers. In addition, the transformation of an existing Molex production plant into a Petit Rocher, Arche., is underway, enabling Phillips-Medisize to keep pace with ever-increasing demands in the United States for manufacturing high-volume diagnostic devices.

Upon completion of these expansions, Phillips-Medisize will offer nearly three million square feet / 280,000 square meters of manufacturing space and R&D capabilities specific to each country and region around the world. The company will also support 600,000 square feet / 55,000 square meters of Class 7 and 8 cleanrooms, which complement existing tool construction sites as well as global quality and regulatory systems. In 2020, Phillips-Medisize completed a new facility in St. Croix Meadows, Wisc., With 285,000 square feet / 26,000 square meters supporting the production of molded components for medical diagnostic customers requiring bulk assembly and packaging. volume of regulated products. The facility also includes an ISO 14644-1 Class 8 cleanroom of nearly 64,000 square feet / 6,000 square meters.

End-to-end capacity expansion

As part of its one-stop shop for medical device manufacturing solutions, Phillips-Medisize focuses on design for manufacturing and assembly excellence. Proven front-end innovation, human factors engineering and quality are built into regulatory compliance to reduce risk and cost to market. Extensive capabilities in complex molding, drug and reagent handling, as well as final packaging and serialization, enable customers to consolidate global supply chains while optimizing go-to-market strategies.

Phillips-Medisize’s combined expertise in plastics, metals, electronics and connectivity facilitates the development of different solutions, including combination devices such as needle injection systems and portable injection technologies. An unwavering commitment to rigorous quality management is reinforced by teams dedicated to the introduction of new products (NPI) at each site. Strategic investments in talent acquisition to support Phillips-Medisize’s continued growth are expected to add at least 1,000 employees globally over the next two years.

Optimization of cutting-edge collaborations

Strong collaborative experience ensures that Phillips-Medisize is at the forefront of the latest advancements in drug delivery devices, diagnostics and MedTech. Today, Credence MedSystems announced a strategic initiative with Phillips-Medisize which includes the ramp-up of production of the Credence Companion® and dual chamber reconstitution systems at the Phillips-Medisize Letterkenny, Ireland site and the new installation of Poland.

“We are excited to take advantage of Phillips-Medisize’s world-class manufacturing as we move towards high-volume automation at the new state-of-the-art facility of Poland,” noted Jeff Tillack, COO at Credence MedSystems. “The ability to increase production close to our operations and our European customers will accelerate the time to market of our innovative solutions to meet the needs of our pharmaceutical customers and their end users. “

In September, GlucoModicum has embarked on a design and development program with Phillips-Medisize for the rapid manufacturing scale-up of its Talisman Needle-Free Continuous Glucose Meter, which uses unique magnetohydrodynamic (MHD) technology. Also last month, Paris-based Eyevensys announced a commitment with Phillips-Medisize to optimize the design, development and high volume manufacturing of its ocular device component that powers the delivery of novel gene therapies for the treatment of various eye diseases.

Phillips-Medisize brings possibilities to life

Phillips-Medisize, a Molex company, brings decades of innovation to leading healthcare and life science companies to develop breakthrough solutions that help people live healthier, more productive lives. On average, the company releases 50 new products per year for its customers, including the first drug delivery device registered with the FDA using a connected health system. Molex brings decades of experience in advanced electronics, connectivity and sensor technologies to help transform medical and pharmaceutical solutions.

About Molex

Molex is a global electronics leader committed to making the world a better, more connected place. Present in more than 40 countries, Molex enables transformative technological innovation in automotive, data center, industrial automation, healthcare, 5G, cloud and consumer devices. Through trusted relationships with customers and industry, unmatched technical expertise, and product quality and reliability, Molex realizes the endless potential of Bond for life. For more information visit


About Julie Gray

Check Also

Fast delivery and logistics rank high for pharmaceutical courier services in Washington DC

Swift Delivery & Logistics, the leader in truck delivery in Washington DC, tops the list …

Leave a Reply

Your email address will not be published.